Literature DB >> 8069298

The neurofibromatosis 2 (NF2) tumor suppressor gene encodes multiple alternatively spliced transcripts.

M J Pykett1, M Murphy, P R Harnish, D L George.   

Abstract

Neurofibromatosis type 2 (NF2) is an autosomal dominantly-inherited disorder predisposing affected individuals to tumors of multiple cell types in the central nervous system, including meningiomas. A candidate tumor suppressor gene for this disorder has recently been cloned; the protein product of this gene has a predicted role in linking integral membrane proteins with the cytoskeleton. Utilizing reverse transcription-polymerase chain reaction (RT-PCR) analyses, we have identified a number of alternatively spliced transcription products encoded by the NF2 gene. These alternative splice variants were detected in RNA isolated from several sources, including primary leptomeningeal tissue and an established line of leptomeningeal cells (LMC). Several of these variants delete previously identified coding regions of this gene. Moreover, two of these splice variants add previously unrecognized exons to the NF2 coding region. These identified splice forms will serve as natural reagents for the functional dissection of the NF2 protein product(s). They also should be considered in studies investigating mutations of this gene in members of NF2 families and in tumor analyses.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8069298     DOI: 10.1093/hmg/3.4.559

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  17 in total

Review 1.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

2.  Analysis of the neurofibromatosis type 2 gene in different human tumors of neuroectodermal origin.

Authors:  L R De Vitis; A Tedde; F Vitelli; F Ammannati; P Mennonna; P Bono; B Grammatico; P Grammatico; P Radice; U Bigozzi; E Montali; L Papi
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

Review 3.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

4.  Effects of splicing mutations on NF2-transcripts: transcript analysis and information theoretic predictions.

Authors:  James R Ellis; Bianca Heinrich; Victor-F Mautner; Lan Kluwe
Journal:  Genes Chromosomes Cancer       Date:  2011-05-11       Impact factor: 5.006

5.  Eleven novel mutations in the NF2 tumour suppressor gene.

Authors:  D Bourn; G Evans; S Mason; S Tekes; L Trueman; T Strachan
Journal:  Hum Genet       Date:  1995-05       Impact factor: 4.132

6.  Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins.

Authors:  L Goutebroze; E Brault; C Muchardt; J Camonis; G Thomas
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

Review 7.  Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival.

Authors:  Ivan Stamenkovic; Qin Yu
Journal:  Curr Protein Pept Sci       Date:  2010-09       Impact factor: 3.272

8.  High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.

Authors:  A B Bianchi; S I Mitsunaga; J Q Cheng; W M Klein; S C Jhanwar; B Seizinger; N Kley; A J Klein-Szanto; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

9.  Identification of three neurofibromatosis type 2 (NF2) gene mutations in vestibular schwannomas.

Authors:  J Sainz; K Figueroa; M E Baser; S M Pulst
Journal:  Hum Genet       Date:  1996-01       Impact factor: 4.132

10.  Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity.

Authors:  Pierig Lepont; John T Stickney; Lauren A Foster; Jin-Jun Meng; Robert F Hennigan; Wallace Ip
Journal:  Mutat Res       Date:  2007-08-06       Impact factor: 2.433

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.